News

AMPAC plans $25 million expansion at is Petersburg plant, adding 150 new jobs

AMPAC Fine Chemicals announced a $25 million expansion of its operations that is expected to add more than 150 new jobs.

The California-based company is a top U.S. manufacturer of active pharmaceutical ingredients. The plant in Petersburg previously was owned by Boehringer Ingelheim Chemicals Inc., which closed it in 2014, but AMPAC reopened the site in 2019.

AMPAC employs about 100 people at the site now, having hired about 50 employees this year to ramp up production of pharmaceutical ingredients. The company expects to add the additional 150 jobs over the next two to three years.

The AMPAC plant is part of a larger, planned node of pharmaceutical manufacturing. The Richmond-based pharmaceutical development company Phlow Corp., which has a partnership with AMPAC, also is planning a production facility adjacent to the AMPAC plant.

Founded last year, Phlow has developed manufacturing processes that reduce the cost of production for active pharmaceutical ingredients. In May 2020, Phlow announced it had received a $354 million federal contract to help build a national, strategic reserve of essential medicines and to make active ingredients for more than a dozen medicines used to treat patients with COVID-19.

Another participant in the pharmaceutical manufacturing partnership is Civica Inc., a nonprofit organization formed by various U.S. health care providers to address chronic, generic drug shortages.

Civica announced in January that it plans to invest $124.5 million to establish its first in-house pharmaceutical manufacturing operation also on Normandy Drive in Petersburg.

Recent News

07/01/2025

ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer

ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need. These positive

07/01/2025

Gary Lowenthal Joins Focused Ultrasound Foundation’s Council

The Focused Ultrasound Foundation is pleased to welcome Gary Lowenthal to its Council, a dedicated group of goodwill ambassadors who work closely with the Board of Directors and staff to provide advice and assist with raising funds and building awareness. Mr. Lowenthal is a retired educator, entrepreneur, and executive with a career spanning education, international service,

06/25/2025

Liquet Medical Closes Oversubscribed Seed Round to Launch Pilot Study Evaluating Real-Time Hemodynamic Monitoring

Liquet Medical, a clinical-stage medical device company developing the Versus™ Catheter — a first-of-its-kind dual-tipped catheter system cleared by the FDA for controlled and selective infusion of fluids into the pulmonary vasculature and hemodynamic monitoring — announced the successful and oversubscribed close of its Seed funding round, which officially closed in May 2025. The capital